Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured

10th Apr 2019 07:20

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured 10-Apr-2019 / 07:20 GMT/BST


Hardman & Co Research: Expanded GPO coverage secured

Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse). Following its acquisition of CellRight, management embarked on a revised commercial strategy to increase sales momentum, and it has recently secured expanded Group Purchasing Organisation (GPO) coverage in the US for DermaPure. TRX should benefit in 2019 from the US and European commercial agreements made with leading orthopaedic company, Arthrex, in 2018. Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/expanded-gpo-coverage-secured/

 

To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.comFollow us on Twitter @HardmanandCo Contacts: Dorothea Hill +44 20 7194 7628 [email protected]

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

797887 10-Apr-2019 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.


Related Shares:

Tissue Regenix Group
FTSE 100 Latest
Value8,275.66
Change0.00